OpinionMay 20, 2019
The Next Wave of Immuno-Oncology
A cutting-edge therapy currently used for blood cancers is now being adapted to fight solid tumors
Stories by Elliot Norry
Elliot Norry has served as Adaptimmune’s chief medical officer since January 2020. Prior to that, he was the company’s acting chief marketing officer, vice president, and head of clinical safety and pharmacovigilance, as well as the leader of its ADP-A2AFP program.